<DOC>
	<DOCNO>NCT00813605</DOCNO>
	<brief_summary>This phase 2 , multicenter , randomize , double-blind , double-dummy , placebo-controlled , three-arm trial conduct United States , Europe , Asia . Approximately 150 eligible KRAS-mutant metastatic colorectal cancer subject fail first line fluoropyrimidine oxaliplatin-based regimen without anti-VEGF therapy randomize 1:1:1 ratio receive AMG 479 placebo plus AMG 655 FOLFIRI , AMG 479 plus AMG 655 placebo FOLFIRI , AMG 479 placebo plus AMG 655 placebo FOLFIRI</brief_summary>
	<brief_title>QUILT-2.018 : Safety &amp; Efficacy FOLFIRI With AMG 479 AMG 655 v FOLFIRI Alone KRAS-mutant Metastatic Colorectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm adenocarcinoma colon rectum patient metastatic disease Mutanttype KRAS tumor screen Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Adequate hematology , renal , hepatic , coagulation function History know presence central nervous system metastases History malignancy Prior irinotecanbased chemotherapy advanced/metastatic disease Prior death receptor agonist , systemic IGF1R agonist set Uncontrolled cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AMG 655</keyword>
	<keyword>AMG 479</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>metastatic cancer</keyword>
	<keyword>antibody-2nd line</keyword>
	<keyword>KRAS</keyword>
	<keyword>adenocarcinoma</keyword>
</DOC>